SCHEMBL1322935

SCHEMBL1322935

CNC(=O)c1ccc(C)c(-c2ccc(NC(=O)[C@H](C)NC)c(=O)n2Cc2cc(C(=O)c3ccc(F)cc3)cc(C(F)(F)F)c2)c1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HTT P42858 1/20 0.36
DDR2 Q16832 4/20 0.32
RAF1 P04049 3/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPK14 Q16539 2/20 0.32
BRAF P15056 3/20 0.31
TLR2 O60603 1/20 0.31
TLR1 Q15399 1/20 0.31
CSF1R P07333 1/20 0.31
PTGER4 P35408 1/20 0.31
VNN1 O95497 1/20 0.31
LMNA P02545 1/20 0.30
TSHR P16473 1/20 0.30
CCR2 P41597 1/20 0.30
ACSS2 Q9NR19 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1322938 1.00 KDM4E (0.36) KDM4ESMN1; SMN2HTTDDR2RAF1
SCHEMBL1322829 0.92 MAPK14 (0.33) MAPK14PTGER4LMNATSHR
SCHEMBL1322833 0.92 MAPK14 (0.33) MAPK14PTGER4LMNATSHR
SCHEMBL1323963 0.90 MAPK14 (0.32) MAPK14PTGER4LMNATSHR
SCHEMBL1323960 0.90 MAPK14 (0.32) MAPK14PTGER4LMNATSHR
SCHEMBL2210254 0.89 KDM4E (0.35) KDM4ESMN1; SMN2HTTDDR2MAPK14
SCHEMBL2210261 0.89 KDM4E (0.35) KDM4ESMN1; SMN2HTTDDR2MAPK14
SCHEMBL1323077 0.88 KDM4E (0.38) KDM4ESMN1; SMN2HTTALDH1A1
SCHEMBL1323082 0.88 KDM4E (0.38) KDM4ESMN1; SMN2HTTALDH1A1
SCHEMBL1322983 0.88 FEN1 (0.39) MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048571-A1 Organic Compounds NOVARTIS AG 2010-02-25 US claimed
US-8058272-B2 Organic compounds NOVARTIS AG (CH) 2011-11-15 US disclosed
US-8058272-B2 Organic compounds NOVARTIS AG (CH) 2011-11-15 US disclosed
US-8058272-B2 Organic compounds NOVARTIS AG (CH) 2011-11-15 US disclosed
US-20100048571-A1 Organic Compounds NOVARTIS AG 2010-02-25 US disclosed
US-20100048571-A1 Organic Compounds NOVARTIS AG 2010-02-25 US disclosed
US-20100048571-A1 Organic Compounds NOVARTIS AG 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048571-A1 Organic Compounds XIAP, BAX, MCL1 KDM4E 3048/4885SMN1; SMN2 1520/4885HTT 3684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.